Raymond James Upgrades Editas Medicine (EDIT) to Outperform, 'Early Data De-Risk EDIT-301'
Tweet Send to a Friend
(Updated - June 12, 2023 1:01 PM EDT)
Raymond James analyst Steven Seedhouse upgraded Editas Medicine (NASDAQ: EDIT) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Steven Seedhouse upgraded Editas Medicine (NASDAQ: EDIT) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
